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REGULAR ARTICLE

Subsequent neoplasms and late mortality in children undergoing
allogeneic transplantation for nonmalignant diseases

1
Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Columbia University, New York, NY; 2Center for International Blood and
Marrow Transplant Research, Department of Medicine, and 3Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI; 4Division of
Pediatric Hematology, Children’s Hospital of Orange County, Orange, CA; 5Hematology Branch, Sarah Cannon Bone and Marrow Transplant Program, Nashville, TN; 6Clinical
Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 7Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center,
Nashville, TN; 8Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 9Division of Blood and Marrow
Transplantation, Center for Cancer and Blood Disorders, Children’s National Medical Center, Washington, DC; 10Children’s Hospital Colorado and University of Colorado,
Aurora, CO; 11Tom Baker Cancer Center, Calgary, AB, Canada; 12Division of Bone Marrow Transplant, Seattle Cancer Alliance, Seattle, WA; 13Department of Hematology,
Christian Medical College, Vellore, India; 14Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health,
Bethesda, MD; 15Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL; 16Texas Transplant Institute, San Antonio, TX; 17Sylvester Comprehensive
Cancer Center, University of Miami Health System, Miami, FL; 18Department of Pediatric Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, MA;
19
Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC; 20Markey Cancer Center, University of Kentucky, Lexington, KY; 21Division of
Hematology/Oncology, College of Medicine, University of Florida, Gainesville, FL; 22Department of Medicine, University Hospitals Case Medical Center and Seidman Cancer
Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; 23Blood and Marrow Transplant Program and Host Defense Program, Division
of Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children’s Hospital, Columbus, OH; 24Department of Pediatrics, University of Cincinnati
College of Medicine, Cincinnati, OH; 25Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
26
Children’s Research Institute, Children’s National Health Systems, Washington, DC; 27Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center,
Durham, NC; 28Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain; 29Center for Cancer and Blood Disorders, Children’s National
Medical Center, Washington, DC; 30St Jude Children’s Research Hospital, Memphis, TN; 31Stanford Health Care, Stanford, CA; 32Division of Hematology/Oncology/Bone
Marrow Transplantation, Department of Medicine, University of Wisconsin–Madison, Madison, WI; 33The Children’s Hospital at Westmead, Westmead, NSW, Australia;
34
Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; 35Division of Hematology/Bone Marrow Transplant, Mayo
Clinic, Rochester, MN; 36Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; 37Centre for Clinical Research Sormland, Uppsala University, Uppsala,
Sweden; 38Division of Pediatric Hematology/Oncology, Department of Pediatrics, School of Medicine, Washington University in St. Louis, St. Louis, MO; 39Hematology
Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom; 40Lawrence S. Bloomberg Faculty of Nursing,
University of Toronto, Toronto, ON, Canada; 41Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL;
42
Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL; 43Division of Hematological Malignancy and Cellular Therapeutics, University of
Kansas Health System, Kansas City, KS; 44Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of
Health, Bethesda, MD; 45Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 46Blood and Cancer Center,
Starship Children’s Hospital, Auckland, New Zealand; 47Simon Cancer Center, Indiana University, Indianapolis, IN; and 48Division of Hematopoietic Stem Cell Transplantation,
National Cancer Center Hospital, Tokyo, Japan

Submitted 13 August 2019; accepted 11 February 2020; published online 12 May
2020. DOI 10.1182/bloodadvances.2019000839.
*B.E.S. and P.S. contributed equally to this work as senior authors.

2084

Data Sharing requests should be e-mailed to the corresponding author, Rachel Phelan
(rphelan@mcw.edu).
The full-text version of this article contains a data supplement.

12 MAY 2020 x VOLUME 4, NUMBER 9

Downloaded from https://ashpublications.org/bloodadvances/article-pdf/4/9/2084/1728713/advancesadv2019000839.pdf by WASHINGTON UNIVERSITY SCHOOL user on 11 September 2020

Justine M. Kahn,1 Ruta Brazauskas,2,3 Heather R. Tecca,2 Stephanie Bo-Subait,2 David Buchbinder,4 Minoo Battiwala,5 Mary E. D. Flowers,6
Bipin N. Savani,7 Rachel Phelan,2,8 Larisa Broglie,1 Allistair A. Abraham,9 Amy K. Keating,10 Andrew Daly,11 Baldeep Wirk,12 Biju George,13
Blanche P. Alter,14 Celalettin Ustun,15 Cesar O. Freytes,16 Amer M. Beitinjaneh,17 Christine Duncan,18 Edward Copelan,19
Gerhard C. Hildebrandt,20 Hemant S. Murthy,21 Hillard M. Lazarus,22 Jeffery J. Auletta,23 Kasiani C. Myers,24,25 Kirsten M. Williams,26
Kristin M. Page,27 Lynda M. Vrooman,18 Maxim Norkin,21 Michael Byrne,7 Miguel Angel Diaz,28 Naynesh Kamani,29 Neel S. Bhatt,30
Andrew Rezvani,31 Nosha Farhadfar,21 Parinda A. Mehta,24,25 Peiman Hematti,32 Peter J. Shaw,33 Rammurti T. Kamble,34 Raquel Schears,35
Richard F. Olsson,36,37 Robert J. Hayashi,38 Robert Peter Gale,39 Samantha J. Mayo,40 Saurabh Chhabra,8 Seth J. Rotz,24,25
Sherif M. Badawy,41,42 Siddhartha Ganguly,43 Steven Pavletic,44 Taiga Nishihori,45 Tim Prestidge,46 Vaibhav Agrawal,47
William J. Hogan,34,35 Yoshihiro Inamoto,48 Bronwen E. Shaw,2,* and Prakash Satwani1,*

We examined the risk of subsequent neoplasms (SNs) and late mortality in children and

Key Points

• Survival after transplantation for NMDs is excellent beyond the first
2 years post-HCT.

nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile
range, 1-11; range, ,1 to 20) from the Center for International Blood and Marrow Transplant
Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and
standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with
expected rates in the general population. Median follow-up of survivors was 7.8 years.
Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other
marrow failure (6%), hemoglobinopathy (15%), immunodeﬁciency (23%), and metabolic/
leukodystrophy syndrome (22%). Ten-year survival was 93% (95% conﬁdence interval [95%
CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%).
Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%);
for other NMDs, incidence was ,1%. Hematologic (27%), oropharyngeal (25%), and skin
cancers (13%) were most common. Leukemia risk was highest in the ﬁrst 5 years
posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after
5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95%
CI, 8.9-13.9) compared with the general population. We report excellent long-term survival
and low SN incidence in an international cohort of children undergoing HCT for NMDs. The
risk of SN development was highest in patients with FA and marrow failure syndromes,
highlighting the need for long-term posttransplantation surveillance in this population.

Introduction
Allogeneic hematopoietic cell transplantation is a curative treatment
option for pediatric and adolescent patients with nonmalignant
diseases (NMDs). Despite continued advances in the field of HCT
and an increasing number of long-term survivors, treatment-related
mortality and late effects remain a challenge. A significant cause of
morbidity after HCT is the development of subsequent neoplasms
(SNs).1 Among children receiving transplants for primary malignancies, exposure to cytotoxic therapy or radiation during initial cancer
treatment followed by myeloablative conditioning before HCT
increases the likelihood of SN posttransplantation. (HCT). Presumably,
children and adolescents receiving transplants for NMDs are at lower
risk for SNs than might be expected in children undergoing HCT for
malignant diseases. However, although a majority of these patients are
not exposed to prior chemotherapy or radiation, graft-versus-host
disease (GVHD), immunosuppressive therapy, and genetic predisposition may also increase the risk of SN posttransplantation.
Numerous studies have described SN incidence in children and
adolescents undergoing HCT for the treatment of primary malignancies2; however, few have examined SN risk in those undergoing
transplantation for NMDs.3 Given the increasing use of HCT for
children with NMDs, data regarding these long-term outcomes are of
high importance. A recent report from the National Institutes of Health
Hematopoietic Cell Transplantation Late Effects Initiative highlighted
gaps in the current literature regarding SNs after HCT.1 Authors cited
a need for longitudinal studies and for comparison of SN risk after HCT
with the risk of new malignancies in the general population.4
The objectives of this study were to examine the incidence of
posttransplantation SNs and report the risk of death after 2 years in
an international cohort of pediatric and adolescent patients with
12 MAY 2020 x VOLUME 4, NUMBER 9

bone marrow failure disorders, hemoglobinopathies, immunodeficiency syndromes, inborn errors of metabolism, and leukodystrophies. We specifically examined whether patients had an increased
risk of developing a new malignancy at any time point and an
increased risk of late mortality compared with the general
population of age- and sex-matched controls. Here we report
contemporary data on a diverse patient population to both inform
decision making and contribute to consensus guidelines about
posttransplantation follow-up surveillance in children and adolescents receiving transplants for NMDs.5

Patients and methods
Data source
The Center for International Blood and Marrow Transplant Research (CIBMTR), a research collaboration between the Medical
College of Wisconsin and the National Marrow Donor Program,
collects data from .450 transplantation centers worldwide.
Participating centers contribute data about individual patients,
their exposures, and their outcomes. Transplant essential data
are collected on all patients and include information on demographics, primary disease, transplantation characteristics, and
posttransplantation outcomes (including SNs, relapse, survival, and
cause of death). Observational studies conducted by the CIBMTR
are performed in compliance with all applicable federal regulations
pertaining to the protection of human research participants.

Study cohort
The study cohorts included in analyses of survival and SNs are
presented in Figure 1. Children and adolescents undergoing first
HCT for treatment of Fanconi anemia (FA), severe aplastic anemia
TRANSPLANTATION OUTCOMES IN NONMALIGNANT DISEASES
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• Cumulative incidence
of SNs is low; however,
there is an increased
risk in those with FA or
marrow failure.

adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for

Center for International Blood and Marrow Transplant Research (CIBMTR)
Registry
Patients 21 years undergoing first allogeneic hematopoietic cell
transplantation for non-malignant disease, (1995 - 2012):
N = 6,028

COHORT: SUBSEQUENT NEOPLASMS

Exclude:
Patients deceased before
two-years post-transplant:
N= 1,524
Patients with 2 years of
follow-up: N= 290

Exclude:
Patients with
incomplete SN data:
N = 47

Final CIBMTR cohort of patients
1 - 20 years included in analysis
of long-term survival:
N = 4,214

Final CIBMTR cohort of patients
1 – 20 years included in analysis
of subsequent neoplasms
N = 5,981

Patients from countries
without available data
on general population
cancer rates:
N = 48

Final CIBMTR cohort of patients
1 – 20 years included in analysis
of relative incidence of SNs
N = 5,933
Figure 1. Cohort selection.

(SAA), other marrow failure disorders, sickle cell disease (SCD),
thalassemia, primary immunodeficiency syndromes (PIDs), histiocytic disorders, or inborn errors of metabolism or leukodystrophy
with data reported to the CIBMTR were eligible for inclusion. A total
of 6028 patients age ,21 years who underwent transplantation
between 1995 and 2012 met inclusion criteria (Figure 1).
For analysis of late mortality and long-term survival, patients who
died (n 5 1524; 25%) or who were lost to follow-up before 2 years
(n 5 251; 5%) were excluded. For analysis of SNs, incidence of
SNs for each NMD group was determined from the time of
transplantation to the time of event. Patients without information on
SNs and those who had an SN diagnosis date that preceded the
date of HCT were excluded. An additional 48 patients were
excluded from calculation of SN standardized incidence ratios
(SIRs) because general population cancer rates were not available
for their countries of origin; these included patients from South
Africa (n 5 33), Venezuela (n 5 7), Mexico (n 5 7), and Croatia (n 5
1). Posttransplantation lymphoproliferative disorder (PTLD) was not
included as an SN. The final population for SIR analysis of SNs
included 5933 patients (Figure 1).

Statistical analyses
The primary objectives of this study were to report the incidence of
late mortality (defined as death in patients surviving at least 2 years
posttransplantation) and the risk of SNs in children and adolescents
2086
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receiving transplants for NMDs and assess whether those risks
were increased relative to the general population of age- and sexmatched controls. Overall survival (OS) was calculated from 2 years
after the date of transplantation until the date of death (or last
contact for those who remained alive). Survival probabilities were
estimated by the Kaplan-Meier method. Standardized mortality
ratios (SMRs) with 95% confidence intervals (CIs) were used to
compare observed mortality in the study population with expected
mortality in the general population of age- and sex-matched controls
in each country. Expected mortality was calculated from standardized actuarial tables in National Vital Statistics Reports6 and the
Human Mortality Database.
In total, 86 pathology reports were requested from CIBMTR sites.
Of these, 15 were removed because of misclassification of SNs.
After review, 71 SN events were eligible for inclusion, 55 of which
had enough accompanying information to be assigned an International Statistical Classification of Diseases and Related Health
Problems, 10th edition (ICD-10), code. For analysis of SN incidence
relative to the general population, the number of person-years at risk
was calculated from the date of HCT until the date of last contact,
SN diagnosis, or death. Incidence rates for all invasive cancers in
the general population were obtained from selected registries
worldwide.7-9 The risk of new malignancy in the study cohort was
compared with that in the general population using in the method of
Breslow et al,12 as described in previous CIBMTR studies.10-12 To
12 MAY 2020 x VOLUME 4, NUMBER 9
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COHORT: LONG-TERM SURVIVAL

Table 1. Patient and transplantation characteristics (N 5 6028)
Characteristic

n (%)

IQR

n (%)
309 (5)

Cy 1 other (no Bu)

1239 (21)

5-11.1

Fludarabine 1 other

493 (8)

Other

115 (2)

Age at transplantation, y

Graft type

Median

6

IQR

1-11
,1 to 20

Range
Sex

Bone marrow
Peripheral blood
Cord blood

3922 (65)
553 (9)
1553 (26)

Donor

Male

3610 (60)

HLA-identical sibling

Female

2418 (40)

Other related

Region of transplantation center
United States

3290 (55)

Canada

195 (3)

Europe

816 (13)

India and Asia

307 (5)

Middle East and Africa

697 (12)

Central and South America

463 (8)

Australia and New Zealand

251 (4)

Other

9 (,1)

Year of transplantation
1995-1999

1763 (29)

2000-2004

1803 (30)

2005-2009

1977 (33)

2010-2012

485 (8)

Primary disease category
Bone marrow failure disorder

2405 (40)

SAA

2298 (38)
482 (8)

Unrelated

1695 (28)

Cord blood

1553 (26)

Bu, busulfan; Cy, cyclophosphamide; SCID, severe combined immunodeficiency.

compute expected numbers of cancers in the population, age, sex,
calendar year, and region-specific incidence rates for all invasive
solid cancers combined and for cancers of specific anatomic sites
individually were applied to the appropriate person-years at risk.
All reported cases of SNs (with or without pathologic confirmation)
that occurred after the date of HCT were treated as events (n 5
71). Observed/expected ratios, also called SIRs, were calculated
for each NMD group, and the exact Poisson distribution was used
to calculate 95% CIs.10 For tumor site–specific SIR calculations,
only cases to which we were able to assign an ICD-10 code were
included (n 5 55). A significance level a of 5% was used
throughout.

1456 (24)

FA

598 (10)

Other marrow failure

351 (6)

Hemoglobinopathy

874 (15)

Thalassemia

574 (10)

SCD

300 (5)

Immunodeficiency syndrome

1415 (23)

SCID

583 (10)

Non-SCID PID

807 (13)

Histiocytic disorder

469 (8)

Metabolic disease, leukodystrophy, other
Metabolic disorder

1334 (22)
476 (8)

Finally, multivariable Cox proportional hazards regression analyses
were used to identify risk factors for SN development across the full
patient cohort and in patients with FA or SAA and are presented as
hazard ratios (HRs) with 95% CIs. Variables included in multivariable analyses were based on past research and known risk factors
for SNs posttransplantation from prior studies. Models were
adjusted for age, donor and stem cell source, myeloablative
conditioning (vs reduced intensity or nonmyeloablative), receipt of
total-body irradiation (TBI), and diagnosis of chronic GVHD. All
analyses were performed with SAS software (version 9.4; SAS
Institute, Cary, NC).

Results

Leukodystrophy

227 (4)

Patient, disease, and transplantation characteristics

Osteopetrosis

150 (2)

A summary of patient, disease, and transplantation characteristics is
presented in Table 1. Median age at HCT was 6 years (interquartile
range [IQR], 1-11; range, ,1 to 20), and median follow-up was
7.8 years (IQR, 5.0-11.1; range, ,1 to 20); 22% of the cohort had
at least 10 years of follow-up. Forty percent of the cohort had
congenital or acquired bone marrow failure disorders, including FA
(10%) and SAA (24%). Patients with hemoglobinopathies comprised 15% of the cohort (SCD, 5%; thalassemia, 10%). Twentythree percent of patients had either SCID or non-SCID PIDs, and
22% had inborn errors of metabolism, leukodystrophy, or

Autoimmune disease

25 (,1)

Other

12 (,1)

Conditioning regimen
None

141 (2)

TBI 1 Cy 6 other

894 (15)

TBI 1 other

117 (2)

Bu 1 Cy

2720 (45)

12 MAY 2020 x VOLUME 4, NUMBER 9

TRANSPLANTATION OUTCOMES IN NONMALIGNANT DISEASES

2087

Downloaded from https://ashpublications.org/bloodadvances/article-pdf/4/9/2084/1728713/advancesadv2019000839.pdf by WASHINGTON UNIVERSITY SCHOOL user on 11 September 2020

Bu 1 other (not Cy)

,1 to 20

Range

Characteristic

7.8

Follow-up of survivors, y
Median

Table 1. (continued)

OS and relative mortality among 2-year survivors
A total of 4214 patients (70%) with at least 2 years of follow-up
were included in analysis of late mortality; 1524 (25%) died before
2 years, and 251 (4%) were excluded because of incomplete data
at 2 years posttransplantation. Of the 25% of patients who died
before 2 years, the primary causes of death were organ failure
(23%) and infection (22%), followed by pulmonary complications
(12%) and GVHD (10%; Table 2). OS probabilities among the
patients still alive after 2 years were 97% (95% CI, 96% to 97%)
and 93% (95% CI, 92% to 94%) at 5 and 10 years, respectively
(Table 3). Long-term survival in this cohort varied based on
underlying NMD. Patients with inborn errors of metabolism or
leukodystrophies had the lowest survival probabilities at each
evaluable time point (Table 3). The most common cause of death in
2-year survivors was organ failure (20%), followed by complications
of primary disease (17%), infection (11%), and GVHD (10%).
Subsequent neoplasms were the cause of death in 6% of cases
(Table 2).
Comparisons of mortality rates in each disease group with rates in
the general population are presented in Table 2. Although long-term
survival was excellent, the study cohort alive at 2 years still had
a fourfold increased incidence of all-cause mortality compared with
age- and sex-matched controls from the general population (SMR,
4.2; 95% CI, 3.7-4.8). Mortality rates for all NMDs were significantly
higher than rates in the general population, with the exception of
patients with thalassemia or autoimmune disease. Increased mortality
rate was most dramatically noted in children with inborn errors of
metabolism or leukodystrophies, whose risks of death were 37- and
25-fold higher than expected, respectively (Table 2).

SNs
Among 5933 patients with median follow-up of 7.6 years (range,
2-20.9), 71 (1.2%) developed SNs. Details of the 71 individual
cases are presented in supplemental Table 1. Incidence of SNs was
highest in children with FA (5.5%), SAA (1.1%), or other marrow
failure disorders (1.7%; Table 4). In patients with hemoglobinopathies, PIDs, metabolic disorders, leukodystrophies, or other NMDs,
SN rates were ,1%. No SNs were observed in patients receiving
transplants for thalassemia. The most frequent SNs were hematologic malignancies, including acute myeloid leukemia (AML; n 5 8),
myelodysplastic syndrome (MDS; n 5 7), and acute lymphoblastic
leukemia (n 5 3). Oropharyngeal cancers, including mouth (n 5 2),
tongue (n 5 5), and hypopharynx (n 5 1), comprised 25% of cases.
Skin cancers, including melanoma (n 5 2), were diagnosed in 9
patients (Table 4).
The observed incidence of SNs posttransplantation was significantly higher than the expected incidence in the general population
(SIR, 11; 95% CI, 8.9-13.9; Table 5). Excess risk was evident in
those receiving transplants for FA (SIR, 50; 95% CI, 34-71),
SAA (SIR, 8; 95% CI, 4-12), or SCD (SIR, 11; 95% CI, 2-33).
Patients with leukodystrophy or histiocytic disorders had 102088

KAHN et al

Table 2. Cause of death <2 vs ‡2 years posttransplantation (N 5 6028)
Primary cause of death
Patients, n
Primary disease
Graft failure

<2 y, n (%)

‡2 y, n (%)

Total, n (%)

1524

251

1775

104 (7)

43 (17)

147 (8)

87 (6)

9 (4)

96 (5)

GVHD

151 (10)

26 (10)

177 (10)

Infection

332 (22)

28 (11)

360 (20)

Pulmonary/ARDS

182 (12)

11 (4)

193 (11)

Organ failure

348 (23)

50 (20)

398 (22)

19 (1)

14 (6)

33 (2)

147 (10)

33 (13)

180 (10)

2 (0)

0 (0)

2 (0)

152 (10)

37 (15)

189 (11)

Secondary malignancy
Other cause
Unknown
Missing

ARDS, acute respiratory distress syndrome.

(95% CI, 1-37) and 14-fold (95% CI, 5-33) higher-than-expected
incidence of SNs, respectively. Posttransplantation SN incidence
was not significantly higher than expected in patients undergoing
transplantation for thalassemia, PIDs, osteopetrosis, or metabolic
disorders (Table 5).
Tumor site–specific comparisons of SNs in the study cohort with
the general population were restricted to the 55 cases assigned
ICD-10 codes. Analysis revealed that risk in the study cohort was
elevated for almost all cancer sites (Table 5). Compared with the
general population, the study cohort had significantly increased
rates of AML (SIR, 23; 95% CI, 9.7-44) and MDS (SIR, 730; 95%
CI, 293 to .1000), as well as increased rates of oropharyngeal,
skin, thyroid, liver, and bladder tumors. Of particular note were
the higher-than-expected rates of tongue (SIR, 490; 95% CI,
159 to .1000) and mouth tumors (SIR, 113; 95% CI, 14-408),
which developed exclusively in patients receiving transplants for
FA or marrow failure syndromes. Patients in the study cohort also had
higher-than-expected rates of nonmelanomatous skin cancer (SIR, 68;
95% CI, 27-140). The incidence of bone cancer and central nervous
system tumors was not significantly higher in the study cohort than
would be expected in the general population.
In the full cohort of patients, multivariable models revealed that TBIbased conditioning was associated with a significantly higher
hazard of SNs. Specifically, patients who received a TBI-based
conditioning regimen had a 2.5-fold higher hazard of developing
a posttransplantation SN compared with those who did not receive
TBI-based conditioning (HR, 2.5; 95% CI, 1.5-4.1; P 5 .0003).
Among patients with FA, nonmyeloablative conditioning was
associated with a 75% reduction in the hazard of SNs (HR, 0.26;
95% CI, 0.1-0.9; P 5 .0271). Development of chronic GVHD in
patients with FA was associated with a 4.8-fold increased hazard of
SN development (HR, 4.8; 95% CI, 2.3-10.4; P ,.0001).
Median time from HCT to SN development was 7.5 years (IQR, 3.510.4; range, 0.04-18.5; Figure 2). Median latency between transplantation and SN was shortest for AML (median, 1.8 years; IQR,
1.0-3.7). Latency was longer for cancers of the oropharynx (median,
10.2 years; IQR, 8.2-14.5), as well as for skin (median, 7.2 years;
IQR, 2.9-7.9) and other solid tumors (median, 8.6 years; IQR, 6.110.6; Figure 2). Information on 71 individual SN cases with details
12 MAY 2020 x VOLUME 4, NUMBER 9
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osteopetrosis. A majority of patients received myeloablative
conditioning (63%); however, only 17% of these regimens included
TBI. A total of 71% of patients received antithymocyte globulin
either as pretransplantation conditioning or as part of GVHD
prophylaxis. Most patients received bone marrow as a stem cell
source (65%). HLA-identical sibling (38%) or unrelated donors
(17%) were most common (Table 1).

Table 3. Survival probabilities at 5 and 10 years in patients alive ‡2 years post-HCT, with corresponding SMRs, by NMD
n (%)

5 y (95% CI)

10 y (95% CI)

SMR (95% CI)

P

n 5 4214

97 (96-97)

93 (92-94)

4.2 (3.7-4.8)

,.0001

SAA

192 (5)

98 (97-99)

95 (93-97)

1.8 (1.3-2.4)

.0009

FA

393 (9)

96 (94-98)

92 (88-95)

4.8 (3.4-6.6)

,.0001

Other marrow failure

242 (6)

95 (91-97)

93 (88-96)

6.4 (3.8-10)

,.0001

Primary disease
Patients alive $2 y post-HCT
Bone marrow failure disorder

Thalassemia

401 (10)

98 (97-99)

98 (97-99)

0.7 (0.3-1.4)

.3942

SCD

247 (6)

97 (94-99)

96 (93-98)

8.3 (3.9-15)

,.0001

SCID

403 (10)

97 (95-98)

93 (90-96)

4.8 (3.0-7.3)

,.0001

Non-SCID PID

607 (14)

97 (96-99)

95 (93-97)

5.0 (3.3-7.4)

,.0001

Histiocytic disorder

273 (6)

98 (96-99)

94 (89-97)

9.3 (4.8-16)

,.0001

Immunodeficiency syndrome

Inborn error of metabolism, leukodystrophy, other
Metabolic disorder

314 (7)

93 (89-95)

86 (81-90)

25 (18-5)

,.0001

Leukodystrophy

143 (3)

89 (83-94)

75 (64-84)

37 (37-53)

,.0001

Osteopetrosis

77 (2)

93 (86-98)

85 (74-93)

11.5 (5.5-21)

,.0001

Autoimmune disease

12 (,1)

100

83 (46-100)

12.9 (0.3-72)

.1498

about primary NMD, pretransplantation conditioning, TBI, and
GVHD is presented in supplemental Table 1.

Discussion
To our knowledge, this is the largest study examining SN incidence
and late mortality in an international cohort of children and
adolescents receiving transplants for NMDs. Findings indicate that

a majority of patients who undergo HCT for treatment of NMDs and
are still alive after 2 years have excellent long-term survival. These
findings, while encouraging, underscore the fact that despite low
cumulative incidence of late mortality, the risk of early death remains
a significant challenge in the pediatric transplantation population.
Furthermore, the risk of death resulting from GVHD, infection, or
organ failure persists over time, particularly in those undergoing
transplantation for inborn errors of metabolism or leukodystrophies.

Table 4. Incidence of SNs by primary NMD with SIRs (N 5 5933)
Primary NMD

n of survivors (median follow-up, y; range)

Total

Reported SNs, n (%)

5933 (7.6; 0-20.9)

71 (1.2)

1429 (7.6; 0-20.8)

SIR (95% CI)

P

11 (9-14)

,.001

Bone marrow failure disorder
16 (1.1)

8 (4-12)

,.001

FA

574 (9.1; 0.2-20.4)

31 (5.4)

50 (34-71)

,.001

Other marrow failure

343 (7.7; 0.6-20.3)

6 (1.7)

15 (5-32)

,.001

SCD

294 (6.1; 0.1-20.1)

3 (1)

11 (2-33)

.005

Thalassemia

572 (5.3; 0.2-20.0)

0 (0)

SCID

575 (7.3; 0.2-20.9)

2 (0.3)

4 (0.5-14)

.196

Non-SCID PID

793 (8.0; 0.2-20.5)

3 (0.4)

4 (0.7-10)

.107

Histiocytic disorder

466 (7.1; 0.5-20.2)

5 (1)

14 (5-33)

,.001

Leukodystrophy

227 (6.1; 0.2-20.2)

2 (0.9)

10 (1-37)

.034

Osteopetrosis

150 (6.9; 0.2-20.2)

1 (0.7)

10 (0.3-56)

.191

Metabolic disorder

474 (8.3; 0.2-20.4)

2 (0.4)

4 (0.5-15)

.172

SAA

Hemoglobinopathy

—

—

Immunodeficiency syndrome

Metabolic disease, leukodystrophy, other

Autoimmune

24 (4.7; 0.3-15.8)

0 (0)

—

—

Other

12 (8.7; 5.5-14.0)

0 (0)

—

—
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Hemoglobinopathy

Table 5. Site-specific tumor incidence with SIRs (N 5 5933; 35 667
person-years)
Tumor site
Head and neck

Reported SN
cases, n (%) or n

SIR (95% CI)*

P

18 (25)
5

490 (159 to .1000)

,.001

Mouth

2

113 (14-408)

,.001

Oropharynx

2

.1000 (309 to .1000)

,.0001

Hypopharynx

1

.1000 (32 to .1000)

.002

Nose, sinuses

1

47 (1.2-264)

.042

7

—

—

Oropharynx, unspecified
Hematologic

19 (27)

Lymphoid leukemia

3

3 (0.65-9)

.143

Myeloid leukemia

8

23 (9.7-44)

,.001

MDS

7

730 (293 to .1000)

,.001

MDS, unspecified

1

—

—

9 (13)

Skin
Melanoma of the skin

2

7 (0.8-25)

.071

Nonmelanoma skin

7

68 (27-140)

,.001

Bone and soft tissue

7 (10)

Connective, soft tissue

2

6 (0.8-23)

.083

Bone

2

6 (0.7-21)

.096

Sarcoma, unspecified

3

—

—

Thyroid

5 (7)

16 (5.2-37)

,.001

GI/GU

7 (10)

Liver

2

28 (3-100)

.005

Cervix uteri

1

13 (0.3-74)

.145

Testis

1

3 (0.1-15)

.607

Bladder

1

42 (1.0-234)

.047

2

—

—

Brain, CNS

2 (3)

2 (0.3-8)

.473

Breast

1 (1)

10 (0.3-58)

.184

Other, unspecified

3 (4)

—

—

GI/GU, unspecified

CNS, central nervous system; GI, gastrointestinal; GU, genitourinary.
*Based on number of SN cases with assigned ICD-10 codes (n 5 55).

Despite our cohort having higher-than-expected mortality when
compared with the general population, a majority of patients who
remained alive 2 years posttransplantation had high survival rates at
both 5 and 10 years. With the exception of patients undergoing
transplantation for FA, the study cohort had a reassuringly low
cumulative incidence of posttransplantation SNs.
The cumulative incidence of mortality in our long-term survivors is
similar to other recent reports of patients undergoing allogeneic
HCT for NMDs. In a recent study examining posttransplantation
mortality in patients still alive at 2 years, the 20-year OS rate by
primary diagnosis was 92% for immune disorders, 91% for SAA,
82.3% for sickle cell anemia or thalassemia, and 68.5% for FA.
When compared with the general population, the relative mortality
in patients undergoing transplantation between 2000 and 2010
was actually higher than in earlier time periods. The authors
suggested this could be related to the relatively lower rate of
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For children in our cohort who received transplants for FA, SAA, or
marrow failure, 10-year survival probabilities were .90%. In our
analysis, which was restricted to patients still alive at 2 years,
survival probabilities at 5 and 10 years for patients with SAA were
98% and 95%, respectively. These rates are substantially higher
than earlier reports of outcomes in SAA,15 which may be related to
the younger age of our cohort or continued improvements in the
transplantation procedure, as has been suggested in other recent
reports. It should be noted that the present analysis, in contrast to
prior studies, did not include 1-year transplantation-related mortality, which may also have contributed to the relatively improved
outcomes. Similar to recent studies reporting survival outcomes
near 100% in children receiving matched sibling donor transplants
for SCD, we observed excellent long-term survival in this group, with
5- and 10-year survival probabilities of 97% and 96%, respectively.16 We observed no excess risk of death in patients receiving
transplants for thalassemia. In 2012, Bernardo et al17 reported
5-year survival of 93% in younger patients undergoing transplantation for thalassemia, which is closer to the probabilities
observed in our cohort.
We observed favorable long-term survival in patients with PIDs,
which has been reported by others, although inconsistently.3,18 Pai
et al19 reported that in patients who receive transplants before the
onset of infection, excellent survival is expected in infants with
SCID. Survival in our cohort was similar to that of the younger
patients.20 Again, differences in mortality risk observed between our
study and earlier studies may in part be attributed to differences in
cohort selection criteria (1- vs 2-year survivors). Few studies have
reported long-term outcomes in patients undergoing transplantation for histiocytic disorders. We observed that survival for these
patients was excellent at both 5 and 10 years (98% and 94%,
respectively).
Ten-year survival probabilities in patients with inborn errors of
metabolism or leukodystrophies ranged from 75% to 86%. In an
analysis of OS in children undergoing cord blood transplantation for
leukodystrophies, Van den Broek et al21 reported similar survival
probabilities to those observed in our cohort despite not restricting
their study to 2-year survivors. Survival probabilities were similar to
what we observed in our cohort, suggesting that the risk of
posttransplantation mortality, which is often highest in the early
posttransplantation period, may persist over time in this patient
population.
Overall, the study cohort had a low incidence of posttransplantation
SNs (1.2%). With median follow-up of nearly 8 years, SN incidence
was 5.5% in patients with FA and 1.1% in patients with SAA.22
These rates are slightly lower than those of prior reports in this
patient population with similar length of follow-up.23 In one of the
earliest studies examining posttransplantation SN rates, Socié
et al24 reported an 8-year SN incidence up to 22% in children
receiving transplants for SAA. More recent studies with longer
follow-up have reported higher rates of SNs, which may reflect the
long latency between transplantation and SN development. In
2014, the European Group for Blood and Marrow Transplantation
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Tongue

childhood death resulting from other causes. Overall, they noted
that the cumulative incidence of late mortality decreased significantly over time from 1990 to 2010.13 In 2007, Bhatia et al14
reported 5- and 10-year survival outcomes in patients with SAA of
96% and 94%, respectively.

Figure 2. Median time to SN development after

AML (N=8)

HCT. Median time to SNs for all new diagnoses was
7.5 years (IQR, 3.5-10.4; range, ,1 to 18.5). Median

ALL (N=3)

time to SNs by tumor type was as follows: AML:
1.8 years (IQR, 1.0-3.7; range, ,1 to 7.5); acute
lymphoblastic leukemia (ALL): 2.7 years (IQR, ,1 to

MDS (N=8)

range, ,1 to 10.2); skin: 7.2 years (IQR, 2.9-7.9;

Skin (N=9)

range, ,1 to 11.3); oropharyngeal: 10.2 years (IQR,
8.2-14.5; range, 1-18.5); solid tumors: 8.6 years
(IQR, 6.1-10.6; range, ,1 to 17.9); and other SNs,
unspecified: 14.6 years (IQR, ,1 to 18.1; range,
,1 to 18.1).
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reported that cumulative incidences of SNs after transplantation in
patients with FA were 21% at 15 years and 34% at 20 years postHCT.25
Our observation that patients with FA had an increased SN risk
compared with the general population is consistent with other
studies of FA patients. Even in the absence of HCT, the underlying
genetic instability associated with FA renders these patients at
increased risk for head and neck tumors, as well as for hematologic
and solid malignancies.26 In patients with FA who undergo HCT,
exposure to TBI or alkylating agents, immunosuppression, and
GVHD development have been associated with SN development.
We observed that chronic GVHD was a significant risk factor for
SN development in patients with FA. The use of non–TBI-based
conditioning regimens is increasingly common in recent decades.
Whether this practice shift will reduce the rates of SNs in this
population remains to be seen.
Rates of posttransplantation SNs were low in patients undergoing
transplantation for SCD or thalassemia. Studies in patients with
thalassemia have reported that rates of posttransplantation SNs are
similar to rates in patients who do not undergo HCT.27 In our cohort,
we did not observe any SNs in patients with thalassemia. Recently,
Keegan et al28 reported a higher incidence of leukemia in patients
with SCD compared with the general population. However, in our
cohort, SN risk after transplantation for SCD was not increased
compared with the general population. It is plausible that treatment
of SCD, a disease that is confined exclusively to the hematopoietic
system, may have reduced the likelihood of developing MDS or
leukemia later on.
Patients with PIDs also had low rates of posttransplantation SNs.
Historically, patients with PIDs may be at a higher risk of developing
PTLD in the early post-HCT period. In our study, the incidence of
SNs in patients receiving transplants for primary immunodeficiencies was ,1%; however, PTLD was not included as an SN for the
12 MAY 2020 x VOLUME 4, NUMBER 9

Oropharyngeal: 10.2
Other solid tumors: 8.6
Other SN: 14.6

purposes of the present study. Patients with histiocytic disorders
had an SN rate of 1.1%, which was significantly higher than
expected in the general population. Oropharyngeal, mucosal, and
nonmelanomatous skin cancers were the most common nonhematologic SNs observed in our cohort. All patients with
oropharyngeal cancers had an underlying diagnosis of FA
(supplemental Table 1). Timing of SN development in our cohort
was similar to that in other reports.29 In addition to early leukemia
and skin cancer, we observed a long-term risk for thyroid,
oropharyngeal, and liver tumors, as well as a persistent risk for
MDS. A majority of nonleukemic SNs occurred $5 years postHCT.
A strength of this study is the large, international cohort of children
and adolescents, with detailed treatment information and long
duration of follow-up. The analysis builds on earlier work from the
CIBMTR, which examined mortality rates in long-term survivors after
HCT for primary malignancy or SAA before 2004.14,30 The present
analysis extends this work, with 8 more years of data in a cohort with
a broader spectrum of NMDs. Similar to other reports, we found that
TBI is still associated with a higher hazard of SNs, and early
posttransplantation mortality rates remain unacceptably high. We
were unable to evaluate pretransplantation organ dysfunction
related to underlying disease, which could have contributed to
survival outcomes, particularly in patients with metabolic syndromes
or leukodystrophies. For data collected through the CIBMTR, there
is central pathology review for SN cases, and we were unable to
obtain enough data to assign ICD-10 codes for 16 of the reported
cases. These SNs were not included in the analysis of relative
incidence; therefore, the true SIR for some NMD groups and some
site-specific cancer diagnoses may have been underestimated.
Long-term follow-up beyond 10 years was only available in a subset
of our cohort, which also may have led to underestimation of SN
risk, because many malignancies often develop beyond 15 years
posttransplantation.27 Additional follow-up will be necessary to
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3.6; range, ,1 to 3.6); MDS: 4.2 years (IQR, 3.8-7.7;

determine longer-term survival and later SN development in this
patient cohort.
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In summary, we report excellent long-term survival in patients still
alive at 2 years, as well as low incidence of posttransplantation SNs,
in an international cohort of children and adolescents undergoing
transplantation for NMDs. These findings are accompanied by
a recognition that early posttransplantation mortality remains
a significant challenge and that the risk for SN development
persists over time. The patients at highest risk of developing SNs
were those who might have had underlying predispositions
to malignancy, specifically patients with FA or marrow failure
disorders. In the full cohort, TBI-based conditioning regimens were
associated with a significantly higher hazard of SN development; in
patients with FA, the hazard of SNs was significantly higher in those
with chronic GVHD. We observed no excess cancer risk in children
receiving transplants for thalassemia, PIDs, osteopetrosis, and
metabolic disorders. The present findings suggest that in the
absence of individual patient susceptibility, the transplantation
procedure itself may not necessarily increase the likelihood of
developing a malignancy. It is important to note that a majority of
nonleukemic SNs developed at least 5 years posttransplantation,
which highlights the need for long-term surveillance and close
follow-up in children and adolescents undergoing transplantation
for NMDs.31
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24. Socié G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow
transplantation for severe aplastic anemia. Blood. 1991;78(2):277-279.
25. Peffault de Latour R, Porcher R, Dalle JH, et al; Pediatric Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic
hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2013;
122(26):4279-4286.
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